Movement disorders:血管周间隙和帕金森病 关系密切

2022-11-25 Freeman MedSci原创 发表于广东省

小的BG-PVS与日常生活中的运动和非运动方面的经验有关

血管周围空间(PVS)是大脑血管周围充满液体的空间,是大脑液体和淋巴废物清除系统的重要通道。在神经退行性疾病患者和研究淀粉样蛋白清除的小鼠模型中,有临床和前临床证据表明,磁共振成像(MRI)上可见的PVS是脑小血管疾病和糖液清除功能障碍的标志。

图1: 论文封面图

除了MRI可见的PVS外,其他成熟的基于神经影像学的脑小血管疾病的标志物包括脑室周围和深部白质增生(WMHs)。

在帕金森病(PD)中,基底神经节区域的PVS负担(BG-PVS)已被认为是运动障碍和认知衰退进展的潜在指标。然而,有关认知方面的研究结果不一,有些研究报告说与PVS视觉负担得分没有明显的相关性。不幸的是,这些研究中有许多是用定性的视觉评分量表来评估BG-PVS的,而这种量表更容易受到评分者偏差以及上限和下限效应的影响。

有趣的是,两项基于人群的大型研究表明,大的(直径>3毫米)与小的(直径≤3毫米)PVS之间存在着病理生理上的差异,尽管在PD中没有具体证明。北曼哈顿研究的结果表明,小PVS的高负担与未来血管事件的风险增加有关,而AGES-Reykjavik研究显示,大PVS与信息处理速度下降和痴呆风险增加有关。

藉此,多伦多大学的Joel Ramirez等人, 在一个多中心的PD患者队列中,探究大型和小型BG-PVS的定量测量、全局认知和运动/非运动特征之间的关联。

他们考察了安大略省神经退行性疾病研究计划中登记的133名帕金森病患者的大、小BG-PVS与运动障碍协会统一帕金森病评定量表(MDS-UPDRS)I-IV部分和认知(蒙特利尔认知评估)之间的关联。

 


图2:论文结果图


他们发现:小BG-PVS的PD患者与MDS-UPDRS第一部分(P = 0.008)和第二部分(均P = 0.02)有关联,而大BG-PVS的患者与MDS-UPDRS第三部分(P < 0.0001)和第四部分(P < 0.001)有关联。

BG-PVS与认知能力不相关。

该研究的重要意义在于发现了:小的BG-PVS与日常生活中的运动和非运动方面的经验有关,而大的BG-PVS则与运动症状和运动并发症有关。


原文出处:
Ramirez J, Berberian SA, Breen DP, et al. Small and Large Magnetic Resonance Imaging–Visible Perivascular Spaces in the Basal Ganglia of Parkinson’s Disease Patients. _Movement Disorders_. Published online April 11, 2022:mds.29010. doi:[10.1002/mds.29010](https://doi.org/10.1002/mds.29010)

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1878533, encodeId=ac5d18e853314, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Oct 31 00:05:33 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784510, encodeId=72801e84510c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu May 25 21:05:33 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738125, encodeId=aa9f1e381257d, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jun 13 22:05:33 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077692, encodeId=0c4020e769206, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 01 03:05:33 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013893, encodeId=9ae8201389353, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 01 19:05:33 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2022-10-31 anminleiryan

    #ERS#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1878533, encodeId=ac5d18e853314, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Oct 31 00:05:33 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784510, encodeId=72801e84510c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu May 25 21:05:33 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738125, encodeId=aa9f1e381257d, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jun 13 22:05:33 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077692, encodeId=0c4020e769206, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 01 03:05:33 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013893, encodeId=9ae8201389353, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 01 19:05:33 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2023-05-25 医者仁心

    #Disord#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1878533, encodeId=ac5d18e853314, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Oct 31 00:05:33 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784510, encodeId=72801e84510c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu May 25 21:05:33 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738125, encodeId=aa9f1e381257d, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jun 13 22:05:33 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077692, encodeId=0c4020e769206, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 01 03:05:33 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013893, encodeId=9ae8201389353, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 01 19:05:33 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2022-06-13 仁心济世
  4. [GetPortalCommentsPageByObjectIdResponse(id=1878533, encodeId=ac5d18e853314, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Oct 31 00:05:33 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784510, encodeId=72801e84510c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu May 25 21:05:33 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738125, encodeId=aa9f1e381257d, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jun 13 22:05:33 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077692, encodeId=0c4020e769206, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 01 03:05:33 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013893, encodeId=9ae8201389353, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 01 19:05:33 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1878533, encodeId=ac5d18e853314, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Oct 31 00:05:33 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784510, encodeId=72801e84510c9, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu May 25 21:05:33 CST 2023, time=2023-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738125, encodeId=aa9f1e381257d, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jun 13 22:05:33 CST 2022, time=2022-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077692, encodeId=0c4020e769206, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 01 03:05:33 CST 2022, time=2022-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013893, encodeId=9ae8201389353, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Aug 01 19:05:33 CST 2022, time=2022-08-01, status=1, ipAttribution=)]
    2022-08-01 cmj8wellington

    #Dis#

    0

相关资讯

Nature:麻省理工学院冯国平团队揭示帕金森病治疗新靶点,靶向丘脑回路可挽救帕金森病运动和情绪缺陷

药物治疗(L-多巴)和脑深部电刺激是目前治疗帕金森病的主要手段,可以有效地改善肢体震颤等运动症状,但是对于非运动症状,例如情绪紊乱收效甚微。

iPSC疗法、新靶点、单细胞测序,帕金森病最新研究进展解读

帕金森病的治疗和诊断一直是十分热门的研究领域,最近帕金森病领域有了一些新的突破。通过这篇文章,我们一起了解下帕金森病领域的一些新发现、新进展。

Neurology:帕金森病患者的运动和非运动症状与健康相关的生活质量的关系

潜在的可治疗的运动和非运动症状,特别是神经精神症状,在PwPD的HRQOL的变化中占了很大一部分。

Movement Disorders:路易体病理和阿尔兹海默病理,如何影响男女的临床表型差异?

使用LB和AD生物标志物,即使在LB或AD病理不在临床预期之内,对于LB疾病和AD的准确临床诊断也是必要的。

Movement Disorders:特发性帕金森病患者尿液中Rab10磷酸化的升高

pT73-Rab10的水平较高与疾病进展的恶化有关。

European Radiology:帕金森病的SMwI MRI前瞻性多中心研究

最近,临床上开发了感光图加权成像(SMwI)技术以改善描绘含铁结构的信噪比和对比度-噪声比。最近的研究进一步表明,SMwI在评估3T下的黑质高浓度方面优于SW。

拓展阅读

Lancet子刊:荷兰帕金森病发病率及空间分布的全国性研究(2017–2022年)

本研究利用多源健康数据,首次全面评估了荷兰2017至2022年帕金森病(PD)发病率及其空间分布,发现发病率总体稳定但存在明显地区差异,且无法用已知环境因素完全解释。

BioScience Trends:帕金森病动物模型中的听力损伤可能与耳蜗传出纤维变化有关

帕金森病模型动物的耳蜗,尤其是其传出神经纤维系统,发生了早期且复杂的病理改变。

中医再亮剑!北京团队解密天麻钩藤饮:先救少突胶质细胞,再护神经元,帕金森“髓鞘-突触”双修复时代开启!

该研究首次将血清药物化学、单细胞转录组、网络药理学与类器官模型整合,阐明TGD“重塑神经元-少突胶质细胞互作”的新机制,为中医“祛风止颤”提供现代注解,也为全球PD复合药物研发贡献可复制的技术范式。

Lancet Neurology:硫唑嘌呤治疗早期帕金森病的概念验证试验,阴性主要终点下的性别差异信号与免疫调控启示

AZA-PD研究虽未支持硫唑嘌呤直接作为帕金森病的治疗选择,但它成功完成了概念验证,打开了通过调节外周免疫系统来干预帕金森病进程的研究大门。

2025帕金森病十大科学研究新进展 | 年终大盘点

神经科学论坛小编系统梳理2025年度最具影响力的十大科研进展,展示人类向帕金森病发起总攻的科学图景。

前沿快讯 | 情绪如何“震颤”?认知怎样“绊脚”?

安徽中医药大学王共强团队通过多模态研究,揭示消极情绪可加剧帕金森病、威尔森病患者震颤,认知负荷会恶化威尔森病患者步态,阐明情绪 - 认知 - 运动整合环路机制,为神经疾病精准干预提供新方向。

2025 共识建议:帕金森病认知障碍的诊断、评估和管理

国外神经内科相关专家小组(统称) · 2025-07-24